

CLAIM AMENDMENTS

1. (Previously amended) A peptide of the formula

Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO: 1)

or

Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO: 2)

2. (Currently amended) A pharmaceutical composition comprising as an active ingredient at least one peptide of the formula

Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO: 1)

or

Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO: 2)

or a pharmaceutically acceptable salt thereof; ~~for treating symptoms caused by neuronal cell loss.~~

3. (Previously amended) The pharmaceutical composition of claim 2 further comprising a pharmaceutically acceptable carrier.

4. (Currently amended) A method for treating the symptoms caused by GP120 mediated neurotoxicity, ~~a loss of neurons~~ comprising administering to a person suffering from ~~a disease causing neuronal cell loss~~ HIV infection a therapeutically effective amount of a people of formula

Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO. 1)

or

Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO: 2)

5. (Previously amended) The method of claim 4 wherein the formula is

Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO: 1)

6. (Previously amended) The method of claim 4 wherein the formula is

Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO:2)

7. (Original) The method of claim 4, wherein the peptide is administered by oral, intranasal,

buccal, parenteral, topical or rectal administration.

8. (New) The method of claim 4 wherein the peptide is administered at from 0.01mg to 1000 mgs per day.

9. (New) The method of claim 4 wherein the peptide is administered at from 0.2 mg to 10 mg per day.

10. (New) A method for treating the symptoms caused by a loss of neurons resulting from Alzheimer's disease comprising administering a therapeutically effective amount of a people of formula

Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO. 1)

or

Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO: 2).